Get started
Author

Xixin Hu

Observed institution: CSPC Pharmaceutical Group
ORCID: 0009-0000-0868-4812
Observed ORCID: 0009-0000-0868-4812
OpenAlex ID: A5147970157
Table S12 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Data from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S4 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S10 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S8 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S13 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S9 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 2 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table 1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S3 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S2 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S10 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 4 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Supplementary Methods from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S8 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S7 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 5 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S5 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S6 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 3 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Table S6 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure S9 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Figure 1 from CRB-701: A Second-generation Nectin-4–Targeted Antibody–Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors
2026 · Zhaopeng Sun, Mo Dan, et al.
Works count: 32
Citation count:
H-index:
I10-index:
Year
Topic
Type